@Article{M-10176,
AUTHOR = {Kilymova, Moldir},
TITLE = {Innovative Horizons in Ulcerative Colitis Treatment: A 2024 Comparative Analysis of Cutting-Edge Therapies from the American Gastroenterological Association},
JOURNAL = {Scientific Research Journal of Medical and Health Science},
VOLUME = {2},
YEAR = {2024},
NUMBER = {2},
ARTICLE-NUMBER = {M-10176},
URL = {https://isrdo.org/journal/SRJMH/currentissue/innovative-horizons-in-ulcerative-colitis-treatment-a-2024-comparative-analysis-of-cutting-edge-therapies-from-the-american-gastroenterological-association},
ISSN = {2584-1521},
ABSTRACT = {The moderate to severe types of ulcerative colitis (UC), a chronic inflammatory bowel disease, provide a substantial burden to patients and healthcare professionals alike. The therapy landscape has changed drastically due to recent developments in small-molecule and biological medicines, which have opened up new possibilities for illness management. The American Gastroenterological Association's (AGA) Evidence Synthesis for 2024 is examined in this publication. It examines the most recent innovative treatments for moderate to severe UC. In this research, we look at the new developments in UC treatment by analysing the safety records, long-term effects, and effectiveness of several medications, such as IL inhibitors, JAK inhibitors, integrin receptor antagonists, and TNF inhibitors.},
DOI = {}
}